Evidence map›Paper›PMID 42076148›Full record

ArticlePharmaceutics2026

Ge11-Modified pH-Sensitive Polymer Micelles: A New Breakthrough in Targeted Therapy for Non-Small-Cell Lung Cancer.

Xingmeng Ma, Zhu Wang, Jingyi Wang, Xingyu Chen, Jinggang Zhang, Dengxue Yang, Shiyi Xu, Xueying Yan

Abstract read
In one paragraph

Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xingmeng MaSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.ORCID 0009-0005-0647-4869
Zhu WangSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.ORCID 0009-0005-8612-2264
Jingyi WangSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.ORCID 0009-0002-6762-4144
Xingyu ChenSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.ORCID 0009-0005-1634-1840
Jinggang ZhangSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Dengxue YangSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.ORCID 0009-0007-4032-2847
Shiyi XuSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.ORCID 0000-0002-7999-3775
Xueying YanSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.ORCID 0000-0002-4231-4564

Funding

College Student Science and Technology Innovation Project, Heilongjiang University of Traditional Chinese Medicine, Preparation and evaluation of glutathione responsive photothermal/photodynamic therapy of mesoporous silica tumor targeting nanoparticles KZ2022-02, 2022.12-2023.12General Project of Heilongjiang Natural Science Foundation, Antagonistic effect of Ge11-conjugated ph-sensitive micelles on non-small cell lung cancer and its mechanism LH2021H102, 2021-07 to 2024-07Heilongjiang Chunyan Youth Science and Technology Talent team project 2022CYQN0028Key Scientific Research Project of Health Commission of Heilongjiang Province, Research on photothermal responsive membrane camouflage anti-tumor drug delivery system based on ferroptotic 20241313020534, 2025-December 31, 2026Research on Cancer Cell Membrane Mimetic Nanoparticles Prepared Based on Synergistic Therapy for Targeted Breast Cancer Treatment - 2025 Provincial Natural Science Foundation of China for Young Scientists Project C QC2025H023
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

doxorubicinEGFRlung cancerpH-responsive micellepolypeptide GE11

Identifiers

PMID42076148
PMCPMC13120265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.